Metacrine, Inc

Metacrine is a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal (GI) diseases. Our most advanced programs target the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. FXR agonism has been investigated in large-scale clinical trials and has shown clinically relevant improvements in non-alcoholic steatohepatitis (NASH), a liver disease that affects 17 million people in the U.S. and is characterized by excess liver fat, inflammation and fibrosis. We believe that potency and continuous target engagement are key to optimizing therapeutic benefit with an FXR targeted therapy. Leveraging our extensive chemistry and biology expertise, we have built a proprietary library of over 2,500 FXR compounds, and have selected two oral FXR candidates from a unique chemical scaffold, MET409 and MET642. With our platform, we believe we can develop differentiated FXR agonist therapies for liver and GI diseases.